Assess the patient's lesions to identify those visually suggestive of skin cancer for which an objective risk assessment would be helpful.
Use DermaSensor to analyze those lesions of concern to receive an "Investigate Further" or "Monitor" result for each lesion
Counsel your patient on next steps, such as further investigating the lesion through a biopsy or specialist referral, or just monitoring the lesion having ruled out the need for an immediate biopsy or referral.
- Simple design, effortless application
- Non-invasive optical spectroscopy
- Beneath the skin, cellular-level analysis
- Objective, simple and immediate result
- 93% sensitivity across common skin cancers1
- 13% improvement in GPs' skin cancer detection1
1Data on file for results from DERM-ASSESS II clinical study and DERM-ASSESS II reader study. DermaSensor demonstrated 93% sensitivity across melanoma, BCC and SCC (100% for melanoma). DermaSensor use was found to increase physicians’ cancer detection sensitivity from 81% to 94%, and this improvement was statistically significant (p = .0009). There was no statistically significant change in the GP’s specificity, or false positive rate, for benign lesions (p = .3558).
DermaSensor’s technology holds the promise of improving early detection of skin cancer by equipping primary care providers with a tool to better assess it.
David Leffell, M.D.
Chief, Section of Dermatologic Surgery
and Cutaneous Oncology, Yale School of Medicine
Scientific Advisory Board, DermaSensor
DermaSensor looks beyond the visual to improve your decision-making and confidence.
According to the results of a study with 57 GPs, skin cancer detection increases by 13% (from 81% to 94% sensitivity) when using DermaSensor, with no significant decrease in specificity.